BORA - UiB

Bergen Open Research Archive

DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response

Bergen Open Research Archive

Show simple item record

dc.contributor.author Dejeux, Emelyne eng
dc.contributor.author Rønneberg, Jo A. eng
dc.contributor.author Solvang, Hiroko Kato eng
dc.contributor.author Bukholm, Ida Rashida Khan eng
dc.contributor.author Geisler, Stephanie eng
dc.contributor.author Aas, Turid eng
dc.contributor.author Gut, Ivo G. eng
dc.contributor.author Børresen-Dale, Anne-Lise eng
dc.contributor.author Lønning, Per Eystein eng
dc.contributor.author Kristensen, Vessela N. eng
dc.contributor.author Tost, Jörg eng
dc.date.accessioned 2011-01-05T10:11:46Z
dc.date.available 2011-01-05T10:11:46Z
dc.date.issued 2010-03-25 eng
dc.identifier.citation Molecular Cancer 2010, 9:68 en
dc.identifier.issn 1476-4598 eng
dc.identifier.uri http://hdl.handle.net/1956/4371
dc.description.abstract Background: Breast cancer is the most frequent cancer in women and consists of a heterogeneous collection of diseases with distinct histopathological, genetic and epigenetic characteristics. In this study, we aimed to identify DNA methylation based biomarkers to distinguish patients with locally advanced breast cancer who may benefit from neoadjuvant doxorubicin treatment. Results: We investigated quantitatively the methylation patterns in the promoter regions of 14 genes (ABCB1, ATM, BRCA1, CDH3, CDKN2A, CXCR4, ESR1, FBXW7, FOXC1, GSTP1, IGF2, HMLH1, PPP2R2B, and PTEN) in 75 well-described pre-treatment samples from locally advanced breast cancer and correlated the results to the available clinical and molecular parameters. Six normal breast tissues were used as controls and 163 unselected breast cancer cases were used to validate associations with histopathological and clinical parameters. Aberrant methylation was detected in 9 out of the 14 genes including the discovery of methylation at the FOXC1 promoter. Absence of methylation at the ABCB1 promoter correlated with progressive disease during doxorubicin treatment. Most importantly, the DNA methylation status at the promoters of GSTP1, FOXC1 and ABCB1 correlated with survival, whereby the combination of methylated genes improved the subdivision with respect to the survival of the patients. In multivariate analysis GSTP1 and FOXC1 methylation status proved to be independent prognostic markers associated with survival. Conclusions: Quantitative DNA methylation profiling is a powerful tool to identify molecular changes associated with specific phenotypes. Methylation at the ABCB1 or GSTP1 promoter improved overall survival probably due to prolonged availability and activity of the drug in the cell while FOXC1 methylation might be a protective factor against tumour invasiveness. FOXC1 proved to be general prognostic factor, while ABCB1 and GSTP1 might be predictive factors for the response to and efficacy of doxorubicin treatment. Pharmacoepigenetic effects such as the reported associations in this study provide molecular explanations for differential responses to chemotherapy and it might prove valuable to take the methylation status of selected genes into account for patient management and treatment decisions. en
dc.language.iso eng eng
dc.publisher BioMed Central eng
dc.rights Attribution CC BY eng
dc.rights.uri http://creativecommons.org/licenses/by/2.0 eng
dc.title DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response eng
dc.type Peer reviewed eng
dc.type Journal article eng
dc.subject.nsi VDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Medisinsk genetikk: 714 nob
dc.rights.holder Copyright 2010 Dejeux et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.rights.holder Dejeux et al eng
dc.type.version Published version eng
bora.peerreviewed Peer reviewed eng
bora.cristinID 340028 eng
bibo.doi http://dx.doi.org/10.1186/1476-4598-9-68 eng
dc.identifier.cristinID 340028 eng
dc.identifier.doi http://dx.doi.org/10.1186/1476-4598-9-68


Files in this item

 
 
 
 
 
 
 

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY Except where otherwise noted, this item's license is described as Attribution CC BY

Search BORA


Browse

My Account